RU2020114751A - Схема введения доз сипонимода - Google Patents

Схема введения доз сипонимода Download PDF

Info

Publication number
RU2020114751A
RU2020114751A RU2020114751A RU2020114751A RU2020114751A RU 2020114751 A RU2020114751 A RU 2020114751A RU 2020114751 A RU2020114751 A RU 2020114751A RU 2020114751 A RU2020114751 A RU 2020114751A RU 2020114751 A RU2020114751 A RU 2020114751A
Authority
RU
Russia
Prior art keywords
dose
stroke
hours
administered
over
Prior art date
Application number
RU2020114751A
Other languages
English (en)
Russian (ru)
Inventor
Дзанг-Хо ЧА
Франк ДАЛЬКЕ
Анне ГАРДИН
Эрик ЛЕГАНЬНЕ
III Карл Йозеф МАЛАНГА
Касра ШАКЕРИ-НЕДЖАД
Эрик ВАЛЛЬСТРЕМ
Кристиан ВОЛЬФ
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2020114751A publication Critical patent/RU2020114751A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
RU2020114751A 2017-09-29 2018-09-27 Схема введения доз сипонимода RU2020114751A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762565269P 2017-09-29 2017-09-29
US62/565,269 2017-09-29
PCT/IB2018/057493 WO2019064217A1 (en) 2017-09-29 2018-09-27 DOSAGE DIAGRAM OF SIPONIMOD

Publications (1)

Publication Number Publication Date
RU2020114751A true RU2020114751A (ru) 2021-10-29

Family

ID=63878729

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020114751A RU2020114751A (ru) 2017-09-29 2018-09-27 Схема введения доз сипонимода

Country Status (11)

Country Link
US (1) US20200306222A1 (ko)
EP (1) EP3687531A1 (ko)
JP (1) JP2020535139A (ko)
KR (1) KR20200062240A (ko)
CN (1) CN111132677A (ko)
AU (1) AU2018343239A1 (ko)
CA (1) CA3074416A1 (ko)
IL (1) IL273382A (ko)
MX (1) MX2020007326A (ko)
RU (1) RU2020114751A (ko)
WO (1) WO2019064217A1 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3972954A1 (en) * 2019-05-21 2022-03-30 Synthon B.V. Siponimod maleic acid and fumaric acid salt
CN112402610A (zh) * 2020-11-20 2021-02-26 睿阜隆(杭州)生物医药有限公司 1-磷酸鞘氨醇受体调节剂在制备治疗糖尿病的药物中的新用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
BRPI0922466A2 (pt) 2008-12-18 2018-10-23 Novartis Ag sais
KR20110112352A (ko) 2008-12-18 2011-10-12 노파르티스 아게 1-（4-｛ｌ-［（ｅ）-4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노］-에틸｝-2-에틸-벤질）-아제티딘-3-카르복실산의 신규한 다형체 형태
KR20170062554A (ko) * 2008-12-18 2017-06-07 노파르티스 아게 1-［4-［1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸］-2-에틸-벤질］-아제티딘-3-카르복실산의 헤미푸마레이트 염
WO2010072703A1 (en) * 2008-12-22 2010-07-01 Novartis Ag Dosage regimen of an s1p receptor agonist
EP3590507A1 (en) 2011-01-07 2020-01-08 Novartis AG Immunosuppressant formulations
EP2809645A1 (en) 2012-02-03 2014-12-10 Novartis AG Process for preparing n-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester
CN106163502B (zh) 2014-04-10 2020-12-01 诺华股份有限公司 免疫抑制剂配方
CA2943598C (en) * 2014-04-10 2023-03-07 Novartis Ag S1p modulator immediate release dosage regimen

Also Published As

Publication number Publication date
IL273382A (en) 2020-05-31
AU2018343239A1 (en) 2020-03-12
US20200306222A1 (en) 2020-10-01
JP2020535139A (ja) 2020-12-03
KR20200062240A (ko) 2020-06-03
CN111132677A (zh) 2020-05-08
WO2019064217A1 (en) 2019-04-04
CA3074416A1 (en) 2019-04-04
EP3687531A1 (en) 2020-08-05
MX2020007326A (es) 2020-09-07

Similar Documents

Publication Publication Date Title
RU2020114750A (ru) Схема введения доз сипонимода
Lu et al. Multicenter, randomized, double‐blind, controlled trial of treatment of active rheumatoid arthritis with T‐614 compared with methotrexate
NO20063329L (no) Tricykliske steroidhormone nukleaer reseptormodulatorer
JP2017503820A5 (ko)
RU2010124593A (ru) Противовоспалительные композиции и комбинации
RU2020114751A (ru) Схема введения доз сипонимода
RU2017138551A (ru) Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента
JP2019501886A5 (ko)
JP2018505882A5 (ko)
NZ754764A (en) Pyrimidine tricyclic enone derivatives for inhibition of rorγ and other uses
JP2015522015A5 (ko)
RU2017100077A (ru) Способы лечения ттп иммуноглобулиновыми одиночными вариабельными доменами и их применение
RU2008122964A (ru) Азитромицин для лечения гранулематозных розовых (красных) угрей
JP2018531605A5 (ko)
RU2003125274A (ru) Применение флумазенила в производстве лекарства для лечения алкогольной зависимости
JP2005533830A5 (ko)
JP2018533601A5 (ko)
MX2022015524A (es) Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas.
Sakuma et al. Drugs of muscle wasting and their therapeutic targets
JPS60184011A (ja) 免疫調節剤
FI3352735T3 (fi) Pitkitetysti vapauttavia olantsapiiniformulaatioita
DE19701619A1 (de) Verwendung von Pramipexol zur Behandlung des restless legs syndroms
JPH11130670A (ja) 骨粗鬆症治療剤
Abdalwahab et al. A study on the role of rivaroxaban in management of venous thromboembolism
JP2008133292A (ja) 痒みを抑制するための薬剤